Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results
Novo Integrated Sciences Provides Update on Certain Current Events
Novo Integrated Sciences’ IoNovo Iodine Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health
BELLEVUE, Wash.--(BUSINESS WIRE)--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the issuance of an unsecured 15-year $70,000,000 promissory note with RC Consulting LLC in favor of SCP Tourbillion Monaco (the “Buyer”), for a lump sum debt funding of $57,000,000. The note provides for a yield (non-compounding) of 1.52% (zero coupon) per annum and a maturity date 15 years from the date of issuance. The Note is unsecured and there is no provision for the conversion of debt, issuance of any class of shares, or the grant of any warrants by the Company to the Buyer.
Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc.
BELLEVUE, Wash.--(BUSINESS WIRE)--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International (‘CCI’), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Services Agreement (the “Agreement”), which includes revenue-sharing potential, with Softhread, Inc., an information technology company which offers a proprietary, patent-pending blockchain and AI-enabled platform that preserves confidentiality and optimizes network security, while enhancing operational efficiency. The Agreement relates to Softhread’s product and service offering applicable to the global medical communities rapidly evolving change into the new era of smart and connected health care delivery, referred to as Health Care 4.0.
BELLEVUE, Wash.--(BUSINESS WIRE)--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the Company has completed the acquisition of Clinical Consultants International LLC (“CCI”), a global consulting firm, based in Boca Raton, Florida, specializing in providing value-added services for the pharmaceutical, biotech, healthcare management, hospital management, medical marketing and strategic planning, health policy, and medical device sectors, in an all-stock transaction.
BELLEVUE, Wash.--(BUSINESS WIRE)--Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem with multiple patient and consumer touchpoints for services and product innovation, today announced that its wholly owned subsidiary, PRO-DIP, LLC (“PRO-DIP”), was issued U.S. Patent No. 11,273,965 by the U.S. Patent and Trademark Office on March 15, 2022. The ‘965 patent relates to PRO-DIP’s novel technology for manufacturing its oral supplement pouches.
BELLEVUE, Wash.--(BUSINESS WIRE)--Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem with multiple patient and consumer touchpoints for services and product innovation, today announced that its wholly owned subsidiary, Novo Healthnet Limited, has been granted a Natural Product Number (NPN) by Health Canada for its IoNovo for Kids pure iodine oral spray branded product line. An NPN is a product license assessed and granted by Health Canada Natural Health Products determined to be safe, effective, of high quality, and eligible for sale in Canada.
BELLEVUE, Wash.--(BUSINESS WIRE)--Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended November 30, 2021.